Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Manzoor

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Journal of Managed Care & Specialty Pharmacy|July 24, 2024
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline settingScott F Huntington, Beenish S Manzoor, Dureshahwar Jawaid, et al.
Leukemia & Lymphoma|September 21, 2023
Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemiaScott F Huntington, Beenish S Manzoor, Justin T Puckett, et al.
Talanta|March 11, 2014
Rapid identification and discrimination of bacterial strains by laser induced breakdown spectroscopy and neural networksS Manzoor, S Moncayo, F Navarro-Villoslada, et al.
SSM. Mental Health|July 13, 2023
Effects of a maternal psychosocial intervention on hair derived biomarkers of HPA axis function in mothers and children in rural PakistanVictoria Baranov, Allison Frost, Ashley Hagaman, et al.
Cancers|September 28, 2024
The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus ObinutuzumabKimberly Guinan, Karine Mathurin, Jean Lachaine, et al.
Cancers|June 26, 2026
Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline SettingScott F Huntington, Justin T Puckett, Beenish S Manzoor, et al.
Medical Care|August 15, 2014
Comparative effectiveness of patient-centered strategies to improve FDA medication guidesMichael S Wolf, Stacy C Bailey, Marina Serper, et al.
Pharmacoeconomics|May 9, 2020
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United StatesSang Kyu Cho, Beenish S Manzoor, Kavita R Sail, et al.
Pharmacoeconomics - Open|November 7, 2025
Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility AnalysisGijs van de Wetering, Carolyn Owen, Versha Banerji, et al.
JCO Oncology Practice|December 20, 2024
Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic LeukemiaScott F Huntington, Joanna M Rhodes, Beenish S Manzoor, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Journal of Managed Care & Specialty Pharmacy|July 24, 2024
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline settingScott F Huntington, Beenish S Manzoor, Dureshahwar Jawaid, et al.
Leukemia & Lymphoma|September 21, 2023
Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemiaScott F Huntington, Beenish S Manzoor, Justin T Puckett, et al.
Talanta|March 11, 2014
Rapid identification and discrimination of bacterial strains by laser induced breakdown spectroscopy and neural networksS Manzoor, S Moncayo, F Navarro-Villoslada, et al.
SSM. Mental Health|July 13, 2023
Effects of a maternal psychosocial intervention on hair derived biomarkers of HPA axis function in mothers and children in rural PakistanVictoria Baranov, Allison Frost, Ashley Hagaman, et al.
Cancers|September 28, 2024
The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus ObinutuzumabKimberly Guinan, Karine Mathurin, Jean Lachaine, et al.
Cancers|June 26, 2026
Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline SettingScott F Huntington, Justin T Puckett, Beenish S Manzoor, et al.
Medical Care|August 15, 2014
Comparative effectiveness of patient-centered strategies to improve FDA medication guidesMichael S Wolf, Stacy C Bailey, Marina Serper, et al.
Pharmacoeconomics|May 9, 2020
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United StatesSang Kyu Cho, Beenish S Manzoor, Kavita R Sail, et al.
Pharmacoeconomics - Open|November 7, 2025
Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility AnalysisGijs van de Wetering, Carolyn Owen, Versha Banerji, et al.
JCO Oncology Practice|December 20, 2024
Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic LeukemiaScott F Huntington, Joanna M Rhodes, Beenish S Manzoor, et al.
Pageof 7